한글목차

심근염의 동향과 예측

세계의 심근염 시장은 2024-2030년의 CAGR이 5.6%로, 2030년까지 추정 19억 3,000만 달러에 달할 것으로 예측됩니다. 이 시장의 주요 촉진요인은 만성질환의 유병률 증가, 헬스케어 인프라에 대한 투자의 증가, 노인 인구의 증가입니다. 세계의 심근염 시장의 미래는 병원, 전문 클리닉, 재택의료 시장에 비즈니스 기회가 있으며, 유망시되고 있습니다.

부문별 심근염 질환

이 조사에는 세계의 심근염 질환의 유형별, 치료법별, 진단별, 최종 사용별, 지역별 예측이 포함되어 있습니다.

심근염 질환 관련 기업 리스트

시장에 참여하고 있는 기업은 제공하는 제품 품질에 기반해 경쟁하고 있습니다. 이 시장의 주요 기업은 제조 시설의 확대, 연구개발 투자, 인프라 개척, 밸류체인 전체에서 통합 기회의 활용에 주력하고 있습니다. 이 전략에 의해 심근염 기업은 수요의 증가에 대응하고, 경쟁력을 확보하고, 혁신적인 제품과 기술을 개발하고, 제조 비용을 삭감하고, 고객 기반을 확대하고 있습니다. 본 리포트에 게재되어 있는 심근염 치료제 기업의 개요는 아래와 같습니다.

• F. Hoffmann-La Roche
• Mylan N.V.
• Teva Pharmaceutical Industries
• Sanofi
• Pfizer
• Glaxosmithkline
• Novartis
• Zydus Cadila
• Astrazeneca
• Johnson & Johnson

심근염 질환

• Lucintel은 만성 심근염이 예측 기간 중 가장 높은 성장을 달성할 것으로 예측하고 있습니다.
• 병원이 최대 부문으로 유지됩니다.
• APAC 지역은 심혈관질환 환자의 증가, 헬스케어 인프라의 지속적 정비, 노년 인구의 증가에 의해 예측 기간 중 가장 높은 성장이 전망됩니다.

아래 11개의 주요 질문에 답변하고 있습니다. :

• Q.1.시장 부문 중 가장 유망하고 고성장인 기회는 무엇인가?
• Q.2.어느 부문이 보다 빠른 페이스로 성장하는가, 또 이유는?
• Q.3.향후 성장이 가속할 것으로 생각되는 지역과 이유는?
• Q.4.시장 역학에 영향을 미치는 주요 요인은 무엇인가? 시장에서 주요 과제와 비즈니스 리스크는?
• Q.5.이 시장에서 비즈니스 리스크와 경쟁의 위협은?
• Q.6.이 시장에서 새로운 동향과 이유는?
• Q.7.시장에서 고객의 수요 변화에는 어떤 것이 있는가?
• Q.8.이 시장에서 새로운 개발과 개발을 선도하고 있는 기업은?
• Q.9.이 시장의 주요 기업은? 주요 기업은 사업 성장을 위해 어떤 전략적 구상을 진행시키고 있는가?
• Q.10.이 시장에서 경쟁 제품에는 어떤 것이 있으며, 재료 및 제품의 대체에 의한 시장 점유율 저하의 위협은 어느 정도 있는가?
• Q.11.과거 5년간 어떤 M&A가 시행되고, 업계에 어떤 영향을 미쳤는가?

목차

제1장 주요 요약

제2장 세계의 심근염 질환 시장 : 시장 역학

• 서론, 배경, 분류
• 공급망
• 업계의 촉진요인과 과제

제3장 2018-2030년의 시장 동향과 예측 분석

• 거시경제 동향(2018-2023년)과 예측(2024-2030년)
• 세계의 심근염 질환 시장 동향(2018-2023년)과 예측(2024-2030년)
• 유형별 세계의 심근염 질환 시장
  • 급성 심근염
  • 만성 심근염
  • 림프구성 심근염
• 치료별 세계의 심근염 질환 시장
  • 약
  • 수술
  • 기타
• 진단별 세계의 심근염 질환 시장
  • 혈액검사
  • 영상 검사
  • 심장 카테터
  • 심근 생검
  • 기타
• 최종 용도별 세계의 심근염 질환 시장
  • 병원
  • 전문 클리닉
  • 홈케어
  • 기타

제4장 2018-2030년의 지역별 시장 동향과 예측 분석

• 지역별 세계의 심근염 질환 시장
• 북미의 심근염 질환 시장
• 유럽의 심근염 질환 시장
• 아시아태평양 심근염 질환 시장
• 기타 지역의 심근염 질환 시장

제5장 경쟁 분석

• 제품 포트폴리오 분석
• 운영상 통합
• Porter's Five Forces 분석

제6장 성장 기회와 전략적 분석

• 성장 기회 분석
  • 유형별 세계의 심근염 질환 시장의 성장 기회
  • 치료별 세계의 심근염 질환 시장의 성장 기회
  • 진단별 세계의 심근염 질환 시장의 성장 기회
  • 최종 용도별 세계의 심근염 질환 시장의 성장 기회
  • 지역별 세계의 심근염 질환 시장의 성장 기회
• 세계의 심근염 질환 시장의 새로운 동향
• 전략적 분석
  • 신제품의 개발
  • 세계의 심근염 질환 시장의 능력 확대
  • 세계의 심근염 질환 시장에서의 합병, 인수, 합병사업
  • 인증과 라이선싱

제7장 유력 기업의 기업 개요

• F. Hoffmann-La Roche
• Mylan N.V.
• Teva Pharmaceutical Industries
• Sanofi
• Pfizer
• GlaxoSmithKline
• Novartis
• Zydus Cadila
• AstraZeneca
• Johnson & Johnson

영문목차

Myocarditis Disease Trends and Forecast

The future of the global myocarditis disease market looks promising with opportunities in the hospital, specialty clinic, and homecare markets. The global myocarditis disease market is expected to reach an estimated $1.93 billion by 2030 with a CAGR of 5.6% from 2024 to 2030. The major drivers for this market are increasing prevalence of chronic disorders, increasing investment for healthcare infrastructure ,and growing number of geriatric population.

A more than 150-page report is developed to help in your business decisions.

Myocarditis Disease by Segment

The study includes a forecast for the global myocarditis disease by type, treatment, diagnosis, end use, and region.

Myocarditis Disease Market by Type [Shipment Analysis by Value from 2018 to 2030]:

• Acute Myocarditis
• Chronic Myocarditis
• Lymphocytic Myocarditis

Myocarditis Disease Market by Treatment [Shipment Analysis by Value from 2018 to 2030]:

• Medication
• Surgery
• Others

Myocarditis Disease Market by Diagnosis [Shipment Analysis by Value from 2018 to 2030]:

• Blood Tests
• Imaging Tests
• Cardiac Catheterization
• Heart Muscle Biopsy
• Others

Myocarditis Disease Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

• Hospitals
• Specialty Clinics
• Homecare
• Others

Myocarditis Disease Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Myocarditis Disease Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies myocarditis disease companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the myocarditis disease companies profiled in this report include-

• F. Hoffmann-La Roche
• Mylan N.V.
• Teva Pharmaceutical Industries
• Sanofi
• Pfizer
• Glaxosmithkline
• Novartis
• Zydus Cadila
• Astrazeneca
• Johnson & Johnson

Myocarditis Disease

• Lucintel forecasts that chronic myocarditis is expected to witness highest growth over the forecast period.

• Hospital will remain the largest segment.

• APAC is expected to witness highest growth over the forecast period due to growing cases of cardiovascular diseases, on-going development of healthcare infrastructure, and rising geriatric population in this region.

Features of the Global Myocarditis Disease Market

• Market Size Estimates: Myocarditis Disease Market size estimation in terms of value ($B).

• Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

• Segmentation Analysis: Myocarditis Disease Market by various segments, such as by type, treatment, diagnosis, end use and region in terms of($B).

• Regional Analysis: Myocarditis Disease Market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

• Growth Opportunities: Analysis of growth opportunities in different types, treatments, diagnosis, end uses, and region.s for the myocarditis disease market.

• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the myocarditis disease market.

• Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1. What is the myocarditis disease market size?

Answer: The global myocarditis disease market is expected to reach an estimated $1.93 billion by 2030.

Q.2. What is the growth forecast for myocarditis disease market?

Answer: The global myocarditis disease market is expected to grow with a CAGR of 5.6% from 2024 to 2030.

Q.3. What are the major drivers influencing the growth of the myocarditis disease market?

Answer: The major drivers for this market are increasing prevalence of chronic disorders, increasing investment for healthcare infrastructure, and growing number of geriatric population .

Q.4. What are the major segments for myocarditis disease market?

Answer: The future of the myocarditis disease market looks promising with opportunities in the hospital, specialty clinic, and homecare markets.

Q.5. Who are the key myocarditis disease market companies?

Answer: Some of the key myocarditis disease companies are as follows:

• F. Hoffmann-La Roche
• Mylan N.V.
• Teva Pharmaceutical Industries
• Sanofi
• Pfizer
• GlaxoSmithKline
• Novartis
• Zydus Cadila
• AstraZeneca
• Johnson & Johnson

Q.6. Which myocarditis disease market segment will be the largest in future?

Answer: Lucintel forecasts that chronic myocarditis is expected to witness highest growth over the forecast period.

Q.7. In myocarditis disease market, which region is expected to be the largest in next 5 years?

Answer: APAC is expected to witness highest growth over the forecast period due to growing cases of cardiovascular diseases, on-going development of healthcare infrastructure, and rising geriatric population in this region.

Q.8. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the myocarditis disease market by type (acute myocarditis, chronic myocarditis, and lymphocytic myocarditis), treatment (medication, surgery, and others), diagnosis (blood tests, imaging tests, cardiac catheterization, heart muscle biopsy, and others), end use (hospitals, specialty clinics, homecare, and others), and region. (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Myocarditis Disease Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Myocarditis Disease Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Myocarditis Disease Market by Type
  • 3.3.1: Acute Myocarditis
  • 3.3.2: Chronic Myocarditis
  • 3.3.3: Lymphocytic Myocarditis
• 3.4: Global Myocarditis Disease Market by Treatment
  • 3.4.1: Medication
  • 3.4.2: Surgery
  • 3.4.3: Others
• 3.5: Global Myocarditis Disease Market by Diagnosis
  • 3.5.1: Blood Tests
  • 3.5.2: Imaging Tests
  • 3.5.3: Cardiac Catheterization
  • 3.5.4: Heart Muscle Biopsy
  • 3.5.5: Others
• 3.6: Global Myocarditis Disease Market by End Use
  • 3.6.1: Hospitals
  • 3.6.2: Specialty Clinics
  • 3.6.3: Homecare
  • 3.6.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Myocarditis Disease Market by Region
• 4.2: North American Myocarditis Disease Market
  • 4.2.4: North American Myocarditis Disease Market by End Use: Hospitals, Specialty Clinics, Homecare, and Others
• 4.3: European Myocarditis Disease Market
  • 4.3.1: European Myocarditis Disease Market by Type: Acute Myocarditis, Chronic Myocarditis, and Lymphocytic Myocarditis
  • 4.3.2: European Myocarditis Disease Market by End Use: Hospitals, Specialty Clinics, Homecare, and Others
• 4.4: APAC Myocarditis Disease Market
  • 4.4.1: APAC Myocarditis Disease Market by Type: Acute Myocarditis, Chronic Myocarditis, and Lymphocytic Myocarditis
  • 4.4.2: APAC Myocarditis Disease Market by End Use: Hospitals, Specialty Clinics, Homecare, and Others
• 4.5: ROW Myocarditis Disease Market
  • 4.5.1: ROW Myocarditis Disease Market by Type: Acute Myocarditis, Chronic Myocarditis, and Lymphocytic Myocarditis
  • 4.5.2: ROW Myocarditis Disease Market by End Use: Hospitals, Specialty Clinics, Homecare, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Myocarditis Disease Market by Type
  • 6.1.2: Growth Opportunities for the Global Myocarditis Disease Market by Treatment
  • 6.1.3: Growth Opportunities for the Global Myocarditis Disease Market by Diagnosis
  • 6.1.4: Growth Opportunities for the Global Myocarditis Disease Market by End Use
  • 6.1.5: Growth Opportunities for the Global Myocarditis Disease Market by Region
• 6.2: Emerging Trends in the Global Myocarditis Disease Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Myocarditis Disease Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Myocarditis Disease Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: F. Hoffmann-La Roche
• 7.2: Mylan N.V.
• 7.3: Teva Pharmaceutical Industries
• 7.4: Sanofi
• 7.5: Pfizer
• 7.6: GlaxoSmithKline
• 7.7: Novartis
• 7.8: Zydus Cadila
• 7.9: AstraZeneca
• 7.10: Johnson & Johnson